|Articles|April 10, 2009

WOTY- Podcast-Howson

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Trending on PharmExec

WOTY- Podcast-Howson

Related Content

Transforming Clinical Trial Design and Avoiding AI Wrappers: Q&A with Angela Schwab

Why 75 Top Pharma Execs Are Ditching Fragmented Marketing Stacks

The Prior Authorization System Fails Patients. There's a Better Way

FDA Approves Beqalzi for Relapsed or Refractory Mantle Cell Lymphoma, Inqovi in Combination with Venetoclax

Beyond the Molecule: The New Competitive Battlefield in Oncology

Trending on PharmExec

Eli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectables

Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu

Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu

FDA Approves Beqalzi for Relapsed or Refractory Mantle Cell Lymphoma, Inqovi in Combination with Venetoclax

Beyond the Molecule: The New Competitive Battlefield in Oncology